Search

Your search keyword '"F.Y. Feng"' showing total 40 results

Search Constraints

Start Over You searched for: Author "F.Y. Feng" Remove constraint Author: "F.Y. Feng" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
40 results on '"F.Y. Feng"'

Search Results

1. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial

3. Model Selection for the Preclinical Development of New Drug–Radiotherapy Combinations

5. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

6. Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)

7. Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC)

8. INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients

9. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology

10. Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial

14. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

15. The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)

16. Evaluating the Evidence to Support Clinical Use of the 22-Gene Genomic Classifier (Decipher) in Prostate Cancer

17. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer

18. Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408

19. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601

20. Comprehensive Analysis of Candidate Surrogate Endpoints in Localized Prostate Cancer: Analysis of 59 Randomized Trials

21. Impact Of Sequencing Of Androgen Receptor-Signaling Inhibition (ARSI) And Ionizing Radiotherapy (RT) In Prostate Cancer: Importance Of Homologous Recombination (HR) Disruption

22. Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

23. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery

24. Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies

25. Prostate Cancer-Specific Mortality Following Salvage Post-Prostatectomy Radiation Therapy: A Competition Between Age and Time to Biochemical Failure

26. Development and Validation of Xenograft-Based Platform-Independent Gene Signatures That Predict Response to Alkylating Chemotherapy, Radiation, and Combination Therapy in Glioblastoma

27. 68Ga-PSMA-11 PET-Based Prostate Cancer Lymph Node Atlas Reveals Patterns of Potential Geographic Miss in Consensus Pelvic Nodal Contours

28. Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer

29. Comparison of Population-Based Observational Studies to Randomized Controlled Trials in Prostate Cancer

33. Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment

34. Genomic Validation of Three-Tiered Sub-Classification of High-Risk Prostate Cancer

35. Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials

36. A Multi-institutional Phase 2 Trial Assessing Quality of Life (QOL) After Electromagnetic Transponder Guided Prostate Stereotactic Body Radiation Therapy (SBRT)

37. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in GS 7-10 Prostate Cancer Treated With Dose-Escalated Radiation Therapy

40. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis

Catalog

Books, media, physical & digital resources